Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. ...
Definium Therapeutics, Inc. (DFTX), formerly Mind Medicine (MindMed) Inc., is a clinical-stage biopharmaceutical company headquartered in New York City, dedicated to advancing the field of psychiatry through the development of psychedelic-inspired therapeutics. The company was founded in 2019 by Jamon Rahn and Stephen Hurst, with a vision to apply modern ...Definium Therapeutics, Inc. (DFTX), formerly Mind Medicine (MindMed) Inc., is a clinical-stage biopharmaceutical company headquartered in New York City, dedicated to advancing the field of psychiatry through the development of psychedelic-inspired therapeutics. The company was founded in 2019 by Jamon Rahn and Stephen Hurst, with a vision to apply modern neuroscience and rigorous clinical research to psychedelic compounds. In January 2026, the company rebranded from MindMed to Definium Therapeutics, signaling a new chapter as it approaches key clinical milestones.
The company's pipeline focuses on addressing significant unmet needs in mental health. Its lead drug candidate, MM120 (lysergide), is currently in Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Three Phase 3 readouts are expected in 2026, which could be transformative for the company. Additionally, MM402, the R-enantiomer of MDMA, is in Phase 1 trials targeting the core symptoms of autism spectrum disorder. This pipeline is designed to provide innovative treatment options for patients who have not responded to conventional therapies.
Financially, Definium has a strong balance sheet with approximately $935 million in working capital and a current ratio of 6.95, indicating ample liquidity to fund ongoing trials. The company has no revenue yet, as it is pre-commercial, and is investing heavily in research and development. The market capitalization stands at around $5 billion, reflecting investor optimism about the potential of its pipeline. Despite current losses, the company's cash position and multiple upcoming catalysts position it for potential growth.
Key leadership includes CEO Robert Barrow, who has been at the helm since June 2021 and has successfully transformed the company into a leading player in psychedelic medicine. Chief Medical Officer Daniel R. Karlin, MD, MA, brings expertise in psychiatry and clinical development. The company also has a dedicated team of 106 employees, operating as a lean yet specialized organization. As Definium moves forward, it aims to establish itself as a pioneer in precision psychiatry, leveraging the therapeutic potential of psychedelics to create new standards of care in mental health treatment.
Gitanjali Ogawa: Good afternoon. I am Gita Jain, Head of Investor Relations, and thank you for joining us today for Definium Therapeutics First Quarter 2026 Financial Results and Recent Highlights Conference Call. [Operator Instructions] This webcast is live on the Investors section of Definium's website at definiutx.com, and a replay will be available after the webcast. Leading the call today will be Rob Barrow, our Chief Executive Officer, who is joined by Dr. Dan Karlin, our Chief Medical Officer; Brandi Roberts, our Chief Financial Officer; and Matt Wiley, our Chief Commercial Officer. During today's call, we will be making certain forward-looking statements, including, without limitation, statements about the potential safety, efficacy and regulatory and clinical progress of our product candidates, our anticipated cash runway and our future expectations, plans, partnerships and prospects. These statements are subject to various risks such as changes in market conditions and difficulties associated with research and development and regulatory approval processes. These and other risk factors are described in the filings made with the SEC and the applicable Canadian securities regulators, including our annual report on Form 10-K and our Form 10-Q filed today. Forward-looking statements are based on the assumptions, opinions and estimates of management at the date the statements are made, including the nonoccurrence of the risks and uncertainties are described in the filings made with the SEC and the applicable Canadian securities regulators or other significant events occurring outside of Definium's normal course of business. You are cautioned not to place undue reliance on these forward-looking statements, which are made as of today, May 7, 2026. Definium disclaims any obligation to update such statements even if management's views change, except as required by law. With that, let me turn the call over to Rob.
Robert Barrow: Thank you, Gita, and thank you all for joining us today. The first quarter of 2026 marked a strong start to what we believe will be a pivotal year for Definium. We remain highly focused on disciplined execution as we have advanced our late-stage clinical programs, prepared for multiple near-term data readouts and continue to build an incredible team to lead our potential commercialization efforts. As we discussed at our Investor and Analyst Day a few weeks ago, Definium is entering a period of meaningful clinical inflection. Our lead program, DT120 ODT, is advancing with 4 ongoing Phase III studies across major depressive disorder, or MDD, and generalized anxiety disorder, or GAD, with top line data from Emerge expected later this quarter, followed by Voyage and Panorama in the third quarter. Our Phase III programs are designed to evaluate outcomes that we believe would represent a meaningful advance for patients, physicians in the field of psychiatry. These include not only the magnitude of symptom improvement but also …
